Oxidative Stress-Related HDL Dysfunction in Hemodialysis: The Clinical Utility of MPO/PON1 and MPO/HDL-C Ratios in Cardiovascular Risk Assessment
 
Yazarlar (4)
Dr. Öğr. Üyesi Elif Azize ÖZŞAHİN DELİBAŞ Tokat Gaziosmanpaşa Üniversitesi, Türkiye
Kader Köse
Erciyes University, Faculty Of Medicine, Türkiye
Cevat Yazici Erciyes University, Faculty Of Medicine, Türkiye
Prof. Dr. Bülent Tokgöz Erciyes University, Faculty Of Medicine, Türkiye
Makale Türü Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Therapeutic Apheresis and Dialysis (Q3)
Dergi ISSN 1744-9979 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 02-2026
Cilt / Sayı / Sayfa 30 / 1 / 78–84 DOI 10.1111/1744-9987.70094
Makale Linki https://onlinelibrary.wiley.com/doi/full/10.1111/1744-9987.70094
UAK Araştırma Alanları
Tıbbi Biyokimya
Özet
Introduction Oxidative stress (OS), inflammation, and lipoprotein dysfunction contribute to the high cardiovascular disease (CVD) risk in chronic kidney disease (CKD) patients undergoing hemodialysis (HD). This study examined whether OS‐related biomarkers—myeloperoxidase (MPO), paraoxonase‐1 (PON1), and homocysteine (HCY)—and their derived ratios (MPO/PON1, MPO/HDL‐C, PON1/HDL‐C) are associated with cardiovascular risk. Methods A case–control study was conducted including 42 HD patients and 42 matched healthy controls. Plasma HCY levels, MPO activity, and PON1 activity were measured, along with lipid profiles. Functional OS ratios were calculated. Results HD patients showed higher MPO activity and HCY levels and lower PON1 activity compared with controls (p < 0.001). MPO/PON1 and MPO/HDL‐C ratios were significantly elevated before and after dialysis, indicating …
Anahtar Kelimeler
dysfunctional HDL | hemodialysis | homocysteine | MPO/PON1 | myeloperoxidase | Paraoxonase-1
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Web of Science 1
Scopus 1
Google Scholar 1
Oxidative Stress-Related HDL Dysfunction in Hemodialysis: The Clinical Utility of MPO/PON1 and MPO/HDL-C Ratios in Cardiovascular Risk Assessment

Paylaş